Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525915 | 0.84 | SLC9A1 (0.48) | POLBMAPTSLC9A1TP53MEN1 | |
| SCHEMBL6521129 | 0.80 | CXCR2 (0.49) | POLBMAPTDPP4MEN1KMT2A | |
| SCHEMBL548231 | 0.78 | POLB (0.69) | POLBMAPTCNR2TP53DPP4 | |
| SCHEMBL3936996 | 0.75 | CXCR2 (0.42) | POLBMAPTCNR2NLRP3DPP4 | |
| SCHEMBL3945937 | 0.75 | HTT (0.52) | POLBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3939564 | 0.71 | HTT (0.48) | POLBMAPTDPP4MEN1KMT2A | |
| SCHEMBL549133 | 0.70 | POLB (0.67) | POLBMAPTTP53DPP4MEN1 | |
| SCHEMBL26914701 | 0.69 | MCHR1 (0.51) | POLBMEN1KMT2AALOX15L3MBTL1 | |
| SCHEMBL395149 | 0.68 | HTT (0.47) | POLBMAPTNLRP3TP53MEN1 | |
| SCHEMBL548342 | 0.68 | POLB (0.60) | POLBMAPTCNR2TP53DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110060017-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-03-10 | — | — | US | claimed |
| US-20110060017-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060017-A1 | NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA3, CHRNA5, CHRNB3 | POLB 3940/4885MAPT 752/4885CNR2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.